Medicover AB (publ) (MCVEF) Stock

About Medicover AB (publ)

Medicover AB (publ) is a comprehensive healthcare and diagnostic services provider with operations spanning across numerous countries, including Germany, Sweden, Poland, Turkey, Belarus, Bulgaria, Georgia, Hungary, Serbia, Moldova, Ukraine, and India. Its business is segmented into two primary divisions: Healthcare Services and Diagnostic Services. The diagnostic arm encompasses a broad spectrum of tests, featuring areas such as allergy and autoimmune diagnostics, bacteriology, parasitology, biochemistry, immunochemistry, blood group diagnostics, transfusion medicine, tumour markers, clinical chemistry, cytology, haematology, histopathology, human genetics, hygiene, immunology, infectious diseases, microbiology, molecular biology, and pharmacology/toxicology. The company maintains a significant physical presence, encompassing 97 clinical laboratories, 733 blood-drawing points, and 26 general clinics operating across 10 countries. Complementing these, its broader healthcare infrastructure features 117 medical clinics, 20 fertility clinics, 52 dental clinics, 25 hospitals, and 25 fitness centers. Medicover caters to a diverse client base, from corporate entities and private individuals to direct patients and public sector payers. Established in 1995, Medicover maintains its headquarters in Stockholm, Sweden.

Medicover AB (publ) is headquartered in SE.

Medicover AB (publ) (MCVEF) stock trades at $27.25 with a market capitalization of $4.14B. The stock is valued at a price-to-earnings (P/E) ratio of 36.01, price-to-book of 5.70, price-to-sales of 1.23. Over the past 52 weeks the stock has ranged between $18.00 and $27.25, and currently trades at its 52-week high. It pays a dividend yielding 0.84%.

On profitability, Medicover AB (publ) generates a return on equity (ROE) of 16.01%, above the typical market average, return on capital employed of 11.99%, an operating margin of 7.13%, a net profit margin of 3.44%.

Official website: www.medicover.com